that drive growth of CNS tumors have allowed growing enthusiasm for the treatment of CNS
malignancies. Despite this energized effort to investigate and treat brain cancer, clinical
outcomes for most patients continue to be dismal. Recognition of diverse tumor subtypes,
behaviors and outcomes has led to an interest in personalized medicine for the treatment of
brain tumors. This new paradigm requires evaluation of the tumor phenotype at the time of …